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ABSTRACT
Although the nucleolar localization of proteins is
often believed to be mediated primarily by
non-specific retention to core nucleolar compo-
nents, many examples of short nucleolar targeting
sequences have been reported in recent years. In
this article, 46 human nucleolar localization se-
quences (NoLSs) were collated from the literature
and subjected to statistical analysis. Of the
residues in these NoLSs 48% are basic, whereas
99% of the residues are predicted to be
solvent-accessible with 42% in a-helix and 57% in
coil. The sequence and predicted protein secondary
structure of the 46 NoLSs were used to train an arti-
ficial neural network to identify NoLSs. At a true
positive rate of 54%, the predictor’s overall false
positive rate (FPR) is estimated to be 1.52%, which
can be broken down to FPRs of 0.26% for randomly
chosen cytoplasmic sequences, 0.80% for randomly
chosen nucleoplasmic sequences and 12% for
nuclear localization signals. The predictor was
used to predict NoLSs in the complete human
proteome and 10 of the highest scoring previously
unknown NoLSs were experimentally confirmed.
NoLSs are a prevalent type of targeting motif that
is distinct from nuclear localization signals and that
can be computationally predicted.
INTRODUCTION
The nucleolus is a prominent non-membrane-contained
nuclear structure known primarily as the site of
ribosome biogenesis and assembly (1). In the past two
decades however, the nucleolus has been shown to be
involved in various other cellular functions including
assembly of diverse ribonucleoprotein particles (RNPs),
cell-cycle progression and proliferation regulation, as
well as the response to numerous forms of cellular stress
(2–6). Many of the processes that occur, at least in part, in
the nucleolus require the re-location, often cyclical or con-
ditional, of nucleoplasmic and even cytoplasmic proteins
to the nucleolus (2–4,7). Consistent with this, the nucleolar
proteome is large with currently over 4500 distinct human
proteins that have been identiﬁed in puriﬁed nucleoli (8)
and has been shown to respond dynamically to various
treatments (9,10). The nucleolus thus accommodates a
large and dynamic volume of cellular trafﬁc, which pre-
sumably requires tight regulation of its protein targeting
mechanisms. However, as highlighted in two recent
reviews, widely accepted mechanisms of protein targeting
to the nucleolus remain elusive (6,11).
In contrast, protein targeting to membrane-bound
cellular compartments is well characterized and a small
number of short targeting sequence motifs are predomin-
antly used. These short targeting motifs are generally
recognized by the import machinery of the target compart-
ment. Such is the case for nuclear localization signals
(NLSs) for targeting across the nuclear envelope (12),
signal peptides for co-translational entry into the secretory
pathway at the endoplasmic reticulum (13) as well as mito-
chondrial targeting peptides (14) and peroxisomal target-
ing signals (15). Protein localization in the nucleolus, on
the contrary, is not generally well understood and is
widely believed to be the result of interaction by high
afﬁnity binding to nucleolar core components such as
ribosomal DNA, RNA or major protein components
(16). Thus, nucleolar localization would result from reten-
tion in the nucleolus rather than targeting to this
compartment.
However, in the past 15 years, numerous reports of un-
related human proteins harbouring nucleolar localization
sequences (NoLSs) have been published (summarized in
Table 1). Not all these motifs have been rigorously tested,
but many have been shown to be sufﬁcient for targeting
reporter proteins to the nucleolus. While some of these
NoLSs have been manually aligned with previously
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been reported. Here, we investigate the characteristics of
these experimentally validated NoLSs and use them as a
training set to computationally predict NoLSs in the entire
human proteome.
MATERIALS AND METHODS
Datasets
Positive examples of NoLSs were manually curated from
the literature and are referred to as the experimentally
validated NoLSs (EVN, listed in Table 1 and detailed in
Supplementary File 1) set.
Three types of negatives were considered:
. Non-NoLS NLSs that were manually curated from the
literature and the NLSdb (17) and are listed in
Supplementary File 2.
. Randomly chosen sequences of length 20 from cyto-
plasmic non-nucleolar proteins as annotated by
Uniprot (18).
. Randomly chosen sequences of length 20 from
nucleoplasmic non-nucleolar proteins as annotated by
Uniprot (18).
Table 1. Experimentally Validated NoLSs (EVN) dataset
Accession Protein name NoLS Targets reporter
protein to nucleolus
a
NP_001012270 BIRC5 MQRKPTIRRKNLRLRRK GFP
NP_006161 NOP2 SKRLSSRARKRAAKRRLG b-Gal (but requires
additional NLS)
NP_005336 HSPA1A FKRKHKKDISQNKRAVRR GFP
NP_937862 ING1b (NoLS-1) DKPNSKRSRRQRNNENR GFP
NP_937862 ING1b (NoLS-2) TPKEKKAKTSKKKKRSKAKA GFP
NP_005238 FGF3 GKGVQPRRRRQKQSPDNLEP N/A
NP_006618 POP4 RHKRKEKKKKAKGLSARQRRELR GFP
NP_945316 PTHLH GKKKKGKPGKRREQEKKKRRT b-gal
NP_003778 NOL4 KEKIQAIIDSCRRQFPEYQERAR N/A
NP_001002 RPS7 RRILPKPTRKSRTKNKQKRPR N/A
NP_001034800 DEDD LKRRRA N/A
NP_001091059 RPP38 KIKKLIPNPNKIRKPPKSKKATPK GFP
NP_478102 CDKN2A QLRRPRHSHPTRARRCP GFP
NP_003133 SSB QESLNKWKSKGRRFKGKGKGNKAAQPGSGKGK PTB-GFP
NP_005560 LIMK2 KKRTLRKNDRKKR GFP
NP_001997 FGF2 RSRKYTSWYVALKR GFP
NP_477352 PI4KA SKKTNRGSQLHKYYMKRRTL Soybean trypsin
inhibitor
NP_002383 MDM2 KKLKKRNK Thioredoxin
NP_003945 MAP3K14 RKKRKKK GFP
NP_078908 SAP30L RRYKRHYK N/A
NP_951038 MDFIC GRCRRLANFPGRKRRRRRR GFP
NP_848927 MTDH (NoLS-1) KSKKKKKKKKKQGE GFP
NP_848927 MTDH (NoLS-2) KQIKKKKKARRET GFP
NP_078805 CDC73 (NoLS-1) RRAATENIPVVRRPDRK GFP
NP_078805 CDC73 (NoLS-2) KKKQGCQRENETLIQRRK GFP
NP_078905 MLF1IP MAPRGRRRPRPHRSEGARRSKNTLERTHS GFP
NP_060239 G2E3 RKHDDCPNKYGEKKTKEK N/A
NP_077289 NOL12 KRKHPRRAQDSKKPPRAPRTSKAQRRR GFP fused to rat
NOL12-NoLS
NP_039252 NRG1 MSERKEGRGKGKGKKKERGSGKK GFP
NP_055318 UTP20 KKKMKKHKNKSEAKKRK GFP
NP_849193 STT3B KQKYLSKKTTKRKRGYIKNKLVFKKGKKISKKTV GFP
NP_068810 RELA EQPKQRGMRFRYKCEGRSAGSIPGER N/A
NP_112578 INO80B HGHGVHKKKHKKHKKKHKKKHH N/A
AAB60345 L1 ORF2 RLKIKGQRKIYQANGKQKK N/A
AAH01024 GNL3 KRPKLKKASKRMTCHKRYKIQKKVREHHRKLRLEAKKQGHKKPRK N/A
NP_002511 NPM1 QDLWQWRKSL GFP
NP_937983 TERT MPRAPRCRAVRSLLR GFP
NP_003277 TOP1 NKKKKPKKE N/A
NP_796375 MIDN QQKRLRRKARRDARGPYHWSPSRKAGRS GFP
NP_004851 FXR2 RPQRRNRSRRRRNR N/A
NP_000347 TCOF1 KRKKDKEKKEKKKKAKKASTKDSESPSQKKKKKKKKTAEQTV GFP
NP_004695 RRP9 GQEHRLGRWWRIKEARNSVCIIPLRRVPVPPAAGS N/A
NP_150241 PML DRPLVFFDLKIDN GFP
NP_061940 GNL3L MMKLRHKNKKPGEGSKGHKKISWPYPQPA
KQNGKKATSKVPSAPHFVHPN
GFP
NP_004251 RECQL4 KQAWKQKWRKK GFP
NP_068778 PPP1R11 HRKGRRR N/A
aIndicates whether this NoLS has been shown to target a reporter protein to the nucleolus when fused to it. The reporter protein chosen is indicated
and references are provided in Supplementary File 1.
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that maximizes coverage while minimizing redundancy
(19,20). Redundancy ﬁltering was performed by ensuring
that all the corresponding full-length proteins from which
the sub-sequences are extracted to generate the datasets are
<30% identical over their entire sequence to any other cor-
responding full-length protein used to generate the dataset.
In addition to this, we also veriﬁed that our datasets are
non-redundant by extending all the sub-sequences con-
sidered to a size of 50 (the length of the longest EVN
NoLS) and aligning them pairwise using the fasta
program (version 35.04) (21). All extended NoLS pairs
have at most 13 exact matches in local alignments, repre-
senting <30% sequence identity between the pairs.
For the purpose of training the ANN, several different
combinations of the datasets were investigated and their
performance compared by cross-validation. The one that
was settled on consists of unbalanced datasets comprising
20 copies of the positive examples, 5 copies of the
non-NoLS NLSs negatives,  1000 cytoplasmic negatives
and 180 nucleoplasmic negatives. When 3-fold cross-
validation was performed, care was taken to ensure that
all copies of a given sequence (for NoLSs and non-NoLS
NLSs which were used in more than one copy) were
placed in the same group.
Encoding
For the sequence encoding, windows of 13 residues in size
were sparsely encoded in a binary manner using a reduced
alphabet of size 12 with the follow groupings: {K, R, Q, P,
H, ED, STY, N, C, W, ILVAMG, F}. For example, the
sequence NSAT would be encoded as the binary vector
000000010000000000100000000000000010000000100000.
This reduced alphabet was chosen to ensure that frequent
residues in NoLSs are represented as singlets while
under-represented residues in NoLSs are grouped by
chemical similarity. Other sequence encodings were con-
sidered but did not outperform the encoding described
here as assessed by cross-validation.
For the sequence encoding, a window size of 13 was
chosen for several reasons: (i) bipartite NLSs are between
15 and 17 residues in length according to Prosite (22) and
thus a window size shorter than this might minimize the
number of NLSs wrongly predicted as NoLSs, (ii) larger
window sizes lead to larger artiﬁcial neural networks
(ANNs) and a higher possibility to overﬁtting, (iii) the
accuracy by 3-fold cross-validation is substantially worse
when the window size is greater than 16 or smaller than
11, and 4) an odd number for the window size makes it
easier to assign a score to the middle residue.
Additional information including protein characteristics
and secondary structure were also considered and encoded
using nine ﬂoating point numbers:
. a representation SL of the length L of the protein
SL¼ 1i fL> 400
otherwise, SL¼ 1 
400 L
400
400 was chosen as a threshold as this is the approximate
average length of human proteins as deﬁned by IPI
version 3.40 (23).
. a representation D of the relative distance between the
sub-sequence considered and the middle of the
full-length protein
D¼
jx   mj
m
where x is the position of the subsequence considered
and m is the position of the middle of the protein.
. and 7 measures of protein secondary structure all pre-
dicted by Jpred (24) over a region R covering the
window of size 13 considered and three ﬂanking
residues on either side:
  the proportion of residues in R predicted as
belonging to an a-helix
  the proportion of residues in R predicted as
belonging to a b-sheet
  the proportion of residues in R predicted as
located in a coil
  the average conﬁdence of the three above predic-
tions over region R, as estimated by Jpred (24)
  the proportion of buried residues in R predicted at
a relative solvent accessibility threshold of >25%
  the proportion of buried residues in R predicted at
a relative solvent accessibility threshold of >5%
  the proportion of buried residues in R predicted at
a relative solvent accessibility threshold of >0%
When only the sequence information is used, a binary
vector of size 156 is created (window of size 13 alphabet
of size 12). If in addition to sequence, protein character-
istics and secondary structure are considered, a vector of
size 165 (156+9) is created.
ANNs
The Stuttgart Neural Network Simulator (SNNS;
http://www.ra.cs.uni-tuebingen.de/SNNS/) was used to
train ANNs for the purpose of predicting NoLSs. Many
different combinations of neural network architecture and
parameters were investigated. Most performed equally
well, indicating that the method is relatively insensitive
to parameter changes, and many of the default settings
were chosen. The combination settled on is described
here. ANNs were built with either 156 or 165 input
nodes (depending on the encoding used, see ‘Encoding’
section), 9 hidden nodes and 1 output node. The chosen
target outputs were 0 for non-NoLSs and 1 for NoLSs.
The learning function used was batch backpropopagation,
the initialization function was Randomize_Weights and
the update function was Topological_Order.
During 3-fold cross-validation, ANNs were trained
until the prediction performance on the validation set
started decreasing ( 4000 cycles).
For the receiver operating characteristic (ROC) plots,
the ANN was trained and validated on all three types of
negatives combined and it is just for testing purposes that
7390 Nucleic Acids Research, 2010,Vol.38, No. 21the three types of negatives were considered separately as
well as combined (see Figure 3).
Characterization of predicted NoLS-containing proteins
For the characterization of predicted NoLS-containing
proteins, ‘experimental’ subcellular localization annota-
tions were downloaded from Uniprot (18) for all human
proteins. DAVID (25) was used to compare the GO bio-
logical process term enrichment between the list of pre-
dicted NoLS-containing proteins that exist in RefSeq and
the list of all human RefSeq proteins that were considered
by our predictor as background.
Cell culture and transfection
The human osteosarcoma cell line U2OS was cultured as
adherent cells in Dulbeccos’s modiﬁed eagle medium
(DMEM) (Invitrogen) supplemented with 10% fetal
bovine serum, 100U/ml penicillin/streptomycin and
2mM L-glutamine. Transfection was done using
Effectene (QIAGEN) as per the manufacturer protocol.
Cloning
The oligonucleotides corresponding to each NoLS con-
sidered (see Supplementary File 3 for their nucleotide se-
quences and Table 4 for their amino acid sequences) were
annealed by ﬁrst heating them at 95 C and then letting
them cool down to room temperature. The resulting
double-stranded DNA was then cloned into pEGFP-C1
(Clontech) using the restriction enzymes Bgl II and Kpn I.
Immunoﬂuorescence
Cells were grown on glass coverslips and ﬁxed with 1%
paraformaldehyde in PBS for 10min. Cells were then
permeabilized in PBS containing 0.5% Triton X-100 for
10min and mounted on slides with Vectashield (Vector
Laboratories Inc.) containing DAPI. Fluorescence
imaging was performed on a DeltaVision Spectris
wideﬁeld deconvolution microscope (Applied Precision),
using a CoolMax charge-coupled device camera (Roper
Scientiﬁc). Cells were imaged using a 60 NA 1.4
Plan-Apochromat objective (Olympus) and the appropri-
ate ﬁlter sets (Chroma Technology Corp.), with 20 optical
sections of 0.5mM each acquired. SoftWorX software
(Applied Precision) was used for both acquisition and
deconvolution.
RESULTS
General NoLS characteristics
A dataset of experimentally validated NoLSs was
assembled by extensive manual curation of the literature.
Reported NoLSs of length >50 residues were discarded as
their critical residues have likely not been precisely deﬁned
and/or the NoLS might form a signal patch and exist only
in the folded protein. The remaining 46 NoLSs are shown
in Table 1. These will be referred to as the experimentally
validated NoLS (EVN) set.
Visual inspection of the EVN sequences reveals a high
proportion of basic amino acids. In fact, 48% of the
residues found in these sequences are lysines or arginines.
The average residue frequency for all amino acids in EVN
sequences is shown in Supplementary File 4.
The secondary structure predictor Jpred 3 (24) was used
to analyze the protein regions that contain NoLSs
(Figure 1). EVN sequences are localized in regions pre-
dicted to be almost uniquely a-helices or coils
(Figure 1A) and found predominantly at the surface of
proteins (Figure 1B). An analysis of the position of experi-
mentally validated NoLSs in full-length proteins shows
that known NoLSs localize predominantly at the ends of
proteins (Figure 1C). In fact, 22 of the 46 NoLSs
examined are found in the 25% of residues closest to the
protein termini. NoLSs are thus localized in protein
regions that are easily accessible.
NoLS vs NLS
NLSs target proteins to the nucleus. Numerous and
diverse NLSs have been reported and mechanisms of rec-
ognition of NLSs have been extensively studied (12,26).
NoLSs and NLSs have very similar amino acid compos-
itions (a high prevalence of basic residues in both cases)
and while there is mounting evidence that these two types
of signals are recognized as different by the cell, little at-
tention has been given to distinguishing and systematically
characterizing both types of signals. NoLSs and NLSs can
be collectively grouped into three classes:
. NLS-only signals that target proteins to the nucleus
but do not cause signiﬁcant accumulation in the nu-
cleolus [e.g. PTMA is nucleoplasmic and harbours a
bipartite and non-NoLS NLS (27)].
. NoLS-only signals that cause proteins to accumulate
in the nucleolus but are unable to mediate nuclear
envelop translocation. These are usually found in
proteins that also contain an NLS-only signal. For
example, the proteins NOP2 (28) and PPP1R11
described below.
. Joint NoLS-NLS regions which can both target
proteins across the nuclear envelope and cause
proteins to accumulate in the nucleolus. For
example, UTP20 is reported to contain overlapping
NLS and NoLS near its C-terminus (29).
To conﬁrm that these signals are necessary and sufﬁ-
cient for this targeting, they are usually fused to reporter
proteins and visualized by microscopy (see Table 1 for
examples of experimentally conﬁrmed NoLSs).
Several proteins are reported to contain two ‘NLSs’,
one of which seems to allow entry into the nucleus (an
NLS-only signal) and the other which targets nuclear
proteins to the nucleolus (an NoLS-only signal). For
example, PPP1R11 (protein phosphatase-1 inhibitor-3) is
mainly nucleolar. It has two basic stretches that have dif-
ferent targeting roles. The most N-terminal basic motif
(residues 32–37) serves as an NLS and the protein accu-
mulates in the cytoplasm when this signal is mutated. In
contrast, a C-terminal motif (residues 94–100) functions as
an NoLS and the protein is nuclear but non-nucleolar
when this motif is absent (30).
Nucleic Acids Research, 2010,Vol.38, No. 21 7391Prediction of NoLSs using ANNs
The EVN dataset was used to investigate whether known
NoLSs can be identiﬁed computationally and predicted at
the proteome level. ANNs were chosen as a machine
learning method to predict NoLSs because they perform
well at pattern recognition tasks and have been used suc-
cessfully to identify other protein targeting motifs (31,32).
For this task, the aim is to differentiate between NoLS
and non-NoLS sequences. For training purposes, the
ANN thus requires both positive examples of NoLSs
(the EVN dataset) and examples of sequences that do
not target proteins to the nucleolus (referred to as the
negative training set). As described in the ‘Materials and
methods’ section, the negative training set was generated
by combining three groups of non-NoLS sequences:
(i) randomly chosen protein sub-sequences of 20 residues
from cytoplasmic proteins not annotated as localizing to
the nucleolus, (ii) randomly chosen protein sub-sequences
of 20 residues from nucleoplasmic proteins not annotated
as localizing to the nucleolus and (iii) reported NLSs for
which there is no evidence that they also localize proteins
to the nucleolus (NLS-only signals, as described above).
As NLSs and NoLSs have similar amino acid compos-
itions, NLSs represent the most difﬁcult group of nega-
tives to predict against. Non-NoLS NLSs used in the
negative training set were identiﬁed by manual curation
of the literature and of NLSdb (17). However, in
assembling this dataset, it became obvious that many
reported NLSs might also be NoLSs (joint NoLS-NLS
regions as described above) or are found in nucleolar
proteins and no investigation has been performed to
check whether these NLSs are also NoLSs. For example,
NLS27 and NLS30 from NLSdb (17) refer to the NLS of
the protein LEF1 described in (33). However, while some
microscopy pictures in (33) show LEF1 accumulating in
structures that resemble nucleoli, and Entrez Gene anno-
tates LEF1 as being nucleolar, no further investigation has
been undertaken to clarify the true nature of the LEF1
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Figure 1. NoLS characteristics. (A) NoLSs are predominantly found in regions predicted by Jpred (24) as a-helices or coils and very rarely in regions
predicted as extended b-strands. (B) NoLSs localize predominantly at the surface of proteins as predicted by Jnet (24) either at relative solvent
accessibility thresholds <25% (JnetSol25), <5% (JnetSol5) or 0% (JnetSol0). (C) NoLSs are found predominantly at the ends of proteins. The error
bars represent standard deviation.
7392 Nucleic Acids Research, 2010,Vol.38, No. 21‘NLS’. Reported NLSs found in proteins localized to the
nucleolus were excluded from the negative training set.
Positive and negative training set sequences were
encoded as described in Figure 2 and the ‘Materials and
methods’ section. ANNs were built using the SNNS
(http://www.ra.cs.uni-tuebingen.de/SNNS/).
Measures of accuracy
Cross-validation. Three-fold cross-validation experiments
were performed to measure the accuracy of the predictor.
The positive and negative datasets were randomly divided
into three non-overlapping sets used respectively for
training, validating and testing the ANN. The reported
accuracy is the average of the different training, validating
and testing combinations. Figure 3 summarizes the per-
formance of the predictor as a ROC plot in which the true
positive rate (TPR) is plotted against the false positive rate
(FPR) of the predictor. The predictor was trained on the
combination of all three types of negative examples
as described above and subsequently tested on this
combination of negatives (points labelled
allNegativeTypesCombined). To investigate how well the
predictor performs on the different types of negatives, in
Figure 3 we also provide a breakdown of their estimated
accuracy separately. This was done by training the pre-
dictor in a cross-validation manner on all three types of
negatives combined and then considering each of these
types of negatives separately for testing. As shown in
Figure 3, including secondary structure information as
well as sequence (solid lines) consistently results in
higher accuracy compared to using only sequence
(dashed lines) for all negative types. As expected, the pre-
dictor performs better on negatives randomly generated
from nucleoplasmic or cytoplasmic non-nucleolar
proteins than when tested with reported NLSs. To yield
low FPRs while maintaining a reasonably high TPR, the
threshold to predict NoLSs was set to an average output
score of 0.8 over 8 consecutive windows (as described in
the ‘Materials and methods’ section and in Figure 2). At
this score, the average TPR is measured to be 54% and the
FPRs are measured to be 0.26% for the randomly chosen
cytoplasmic sequences, 0.80% for the randomly chosen
nucleoplasmic sequences and 12% for the NLSs.
Independent validation on NoLS-containing proteins of
human-infecting viruses. Numerous and diverse viral
proteins have been shown to localize in the nucleoli of
their host’s cells (34). Viral proteins that have an experi-
mentally identiﬁed and validated NoLS were used as an
independent test of our human-trained predictor. As
shown in Table 2, all NoLS-containing viral proteins con-
sidered were predicted to harbour at least one NoLS that
overlaps with the experimentally validated NoLS.
Independent experimental validation of human
proteins. The entire EVN dataset was encoded by con-
sidering both sequence and elements of structure and
used to train an ANN which was then applied to the
whole human proteome as deﬁned by IPI version 3.40
(23). Supplementary File 5 shows the list of human
proteins predicted to harbour a NoLS. The
proteome-wide prediction of NoLSs may also be
searched and downloaded from http://www.compbio
.dundee.ac.uk/www-nod/.
Figure 2. Prediction of NoLSs using an ANN. (A) Sequence windows
of size 13 overlapping with an offset of 1 are sparsely encoded into
binary vectors of size 165 based on their amino acid sequence, position
within the full-length protein sequence and elements of secondary struc-
ture. (B) The encoded vectors are fed to the ANN which outputs one
score for each input window, attributed to the central residue of the
window. (C) Peptides of length 20 are predicted as NoLSs if the
average score of the 8 windows of size 13 they contain is >0.8.
Figure 3. ROC plots. The predictor was trained by 3-fold
cross-validation using all types of negatives combined. The true
positive rates (TPRs) versus false positive rates (FPRs) are plotted
for the three different types of negatives tested collectively
(allNegativeTypesCombined) and separately: randomly chosen cyto-
plasmic sequences (referred to as cyto), randomly chosen nucleoplasmic
sequences (referred to as nuc) and curated non-NoLS NLSs (labelled
nls). The accuracy measures of two encodings are shown: encodings
based only on sequence (Seq) and encodings based on both sequence
and additional structure elements (Seq-Struct). The diagonal line indi-
cates the performance that would be expected at random.
Nucleic Acids Research, 2010,Vol.38, No. 21 7393The predicted human NoLSs were ranked by score and
ten of the highest scoring human NoLSs were chosen for
experimental validation. Amongst the highest scoring
NoLSs, care was taken to select diverse proteins including
uncharacterized proteins (e.g. RNF213, C1orf35), mainly
cytoplasmic proteins (AP3D1, SRP72), nucleoplasmic
proteins (SMARCA2, CEBPZ) and a nucleolar protein
for which no NoLS has been described (RBM34). These
proteins selected for experimental validation are shown in
Table 3 and the sequences of their NoLSs are shown in
Table 4. Their respective high-scoring NoLSs were cloned
downstream of GFP, expressed in U2OS cells and
visualized by microscopy. GFP alone as well as a fusion
protein of GFP cloned upstream of a region of protein
RBM34 that is not predicted to be a NoLS (residues
324–345 of RBM34) were used as negative controls. As
shown in Figure 4 and Supplementary File 6, all predicted
NoLSs that were successfully cloned are capable of
causing the accumulation of the GFP fusion protein in
the nucleolus. The negative controls GFP and
GFP-RBM34 (324–345) do not accumulate in the nucle-
olus. Interestingly, while all the predicted NoLS fusion
proteins tested display a strong signal in the nucleolus,
the extent of nucleoplasmic and cytoplasmic accumula-
tions vary considerably for the different NoLSs. As the
number of experimentally validated NoLSs increases in
the future, it will become possible to investigate the dif-
ferences between these signals and to determine whether
they are NoLS-only or joint NoLS-NLS signals.
In choosing the candidates for experimental validation,
we also noticed that USP36 (described in Table 3), a high
scoring candidate, has been recently validated by an
Table 2. Positions of experimentally validated and computationally predicted viral NoLSs
Protein
name
Virus Accession Predicted
NoLS
position
Experimentally
determined NoLS
position
Reference for
experimentally
determined
NoLS position
tat HIV NP_057853 43–68 48–61 (43)
rev HIV NP_057854 28–57 33–52 (44)
rex HTLV-1 NP_057863 1–26 1–20 (45)
NS1A Inﬂuenza A P03495 208–237 216–237 (46)
US11 HSV1 NP_044674 86–105, 113–160 88–125 (47)
RL1 HSV1 P08353 1–22 1–16 (48)
ORF57 HVS NP_040259 114–139 91–94, 119–128 (11,49)
Table 3. NoLSs chosen for experimental validation
Protein
name
Accession NoLS
score
Subcellular localization
of protein if known
Function/ process
of protein if known
Reference for
localization/
process
annotations
NoLS cloned
successfully
Experimentally
validated as
nucleolar-targeting
RBBP6 Q7Z6E9-4 0.981 N/A N/A N/A Yes Yes
RNF213 Q9HCF4-3 0.977 N/A N/A N/A Yes Yes
C1orf35 Q9BU76-1 0.976 N/A N/A N/A Yes Yes
DDX10 Q13206 0.970 N/A RNA helicase (50) Yes Yes
SF3B2 Q13435 0.966 Spliceosomal complex RNA splicing (51–53) Yes Yes
RBM34 P42696 0.966 Nucleolar (inferred
from electronic
annotation)
RNA binding (inferred from
electronic annotation) (18)
(18) No N/A
CEBPZ Q03701 0.959 Nucleus Transcription (54) Yes Yes
SMARCA2 P51531-2 0.958 Nucleoplasm Regulation of transcription (55) Yes Yes
AP3D1 O14617-4 0.957 Golgi apparatus Intracellular protein
transport
(56) Yes Yes
SRP72 O76094 0.950 Mainly cytoplasmic
but nucleolar for
complex assembly
Signal particle recognition
binding
(57) Yes Yes
USP36 Q9P275-2 0.931 Nucleolar Ubiquitin-dependent protein
degradation (inferred from
electronic annotation) (18)
(18,58) N/A Yes [independently
validated (35)]
Table 4. Sequences of NoLSs chosen for experimental validation
Protein
name
NoLS sequence chosen for experimental validation
RBBP6 SQDSKKKKKKKEKKKHKKHKKHKKHKKH
RNF213 SWTVQESKKKKRKKKKKGNKSASSE
C1orf35 HRKSKKEKKKKKKRKHKKEKKKKDKEHRRP
DDX10 KKHSHRQNKKKQLRKQLKKPEWQVERE
SF3B2 GRSTVSVSKKEKNRKRRNRKKKKKPQRVRGVSSE
RBM34 KAVLLKTKKKGQKKSGRPKKQRKQK
CEBPZ AKSIIKKKKHFKKKRIKTTQKTKKQRK
SMARCA2 QAQAAKEKKKRRRRKKKAEENAEGG
AP3D1 RRHRQKLEKDKRRKKRKEKEERTKGKKKSKK
SRP72 QPKEQGQGDLKKKKKKKKGKLPKNYDPK
7394 Nucleic Acids Research, 2010,Vol.38, No. 21independent group. Endo and colleagues experimentally
identiﬁed a functional NoLS between positions 1076 and
1091 of USP36 (35), while we predict an NoLS between
residues 1073 and 1102.
Characteristics of NoLS-containing proteins
Analysis of whole-proteome predictions of NoLS re-
veals that a signiﬁcantly larger proportion of proteins
annotated as nucleolar are predicted to contain a NoLS
than proteins annotated as localized in all other major
cellular compartments (Figure 5). Of proteins annotated
as nucleolar in Uniprot (18), 54% are predicted to
harbour a NoLS. Thirty-nine percent of nuclear-
annotated human proteins and 43% of nucleoplasmic or
nuclear envelope human proteins are predicted to contain
a NoLS. Since the nucleolus is contained within the
nucleus, it is likely that many nucleolar proteins are still
Figure 4. Experimental validation by microscopy. (A) Fusion constructs of NoLSs chosen for experimental validation and successfully cloned
downstream of GFP (Table 3) were transfected into U2OS cells and the resulting proteins were visualized by microscopy [GFP-NoLS() labelled
columns]. The DAPI columns show staining of the DNA in these cells. (B) GFP and GFP-RBM34(324–345) were used as negative controls. The bars
represent 15mm.
Nucleic Acids Research, 2010,Vol.38, No. 21 7395simply annotated as nuclear. As for the nucleoplasmic or
nuclear envelope proteins predicted to have a NoLS,
further experiments and a higher coverage of the localiza-
tion annotations will be required to determine whether
these proteins can also localize to the nucleolus or repre-
sent false-positive predictions. Amongst cytoplasmic
proteins, between 25% (cytosolic proteins) and 5% (per-
oxisomal proteins) are predicted to contain NoLSs. While
some of these proteins surely represent false-positive
predictions, others are likely to represent true
NoLS-containing proteins that might conditionally
localize to the nucleolus. Numerous such examples have
been reported (36–42).
In addition to the Uniprot localization annotations
which are predominantly derived from microscopy experi-
ments reported in the literature, we have also mapped our
predictions of NoLSs onto the quantitative proteomic
analysis of subcellular proteome localization described
recently (10). In this study, the relative abundance of
proteins in different cellular compartments was
measured by harvesting nucleolar, nucleoplasmic and
cytoplasmic cellular extracts each grown in the presence
of amino acids labelled with different isotopes and then by
pooling together the different fractions and analysing
them by mass spectrometry. Table 5 shows the fraction
of proteins that harbour at least one NoLS depending
on their relative abundance ratios in the nucleolus.
Similar to the Uniprot annotations, 48% of proteins
that are both more nucleolar than nucleoplasmic and
more nucleolar than cytoplasmic are predicted to
harbour a NoLS. In contrast,  25% of proteins that are
more nucleoplasmic or cytoplasmic than nucleolar have a
predicted NoLS and only 16% of proteins that are more
nucleoplasmic and cytoplasmic than nucleolar harbour a
predicted NoLS.
Signiﬁcantly enriched Gene Ontology (GO) biological
process annotations of all predicted NoLS-containing
human proteins are shown in Table 6. The most prevalent
terms associated with predicted NoLS-containing proteins
involve transcription, processing of RNA and regulation
of chromatin which agree well with the biological process
annotations of many of the proteins that contain the EVN
sequences.
DISCUSSION
NoLSs are emerging as a predominant mechanism in the
targeting of proteins to the nucleolus. Through careful
curation of the literature, we have identiﬁed 46 NoLSs,
most of which are required for nucleolar targeting of the
proteins that encode them and can target non-nucleolar
reporter proteins to the nucleolus. As a group, these
NoLSs contain a high proportion of basic amino acids
making them similar to NLSs. Because of this similarity,
NLSs and NoLSs are often perceived as analogous and
interchangeably used to annotate proteins. In particular,
short basic stretches in proteins are often assumed to be
NLSs and even when experimental validation is per-
formed, often no attention is given to the particular
intra-nuclear localization of the protein even though this
provides valuable clues about its function in the cell.
Because of this, numerous NoLSs are annotated as NLSs.
Given the very different nature of their target compart-
ments, the similarity between NLSs and NoLSs is
Figure 5. Characteristics of predicted NoLS-containing proteins. For all cellular compartments considered, the fraction of proteins predicted to
harbour a NoLS is shown. Protein counts for each compartment are indicated in parenthesis beside the compartment name. The compartment
groups labelled with an asterisk include proteins annotated as being in this and any other compartment except the nucleolus. The 261 proteins in the
nucleolus group represent all proteins annotated as being nucleolar regardless of any other localization annotations they may have (indicated by
double asterisks). The error bars were determined by bootstrap.
7396 Nucleic Acids Research, 2010,Vol.38, No. 21somewhat surprising: NLSs specify translocation across
the nuclear envelope, a double membrane surrounding
the nucleus, whereas NoLSs ensure accumulation in the
nucleolus, a membrane-less subcompartment within the
nucleus. The similarity between NLSs and NoLSs has
likely delayed the systematic characterization of NoLSs
because of the extra difﬁculty of identifying clear and
meaningful examples of both true NoLSs and true
non-NoLSs. To overcome this problem, we have per-
formed extensive curation of the literature making
possible the accurate prediction of these motifs on a
proteome-wide level. In future experiments, it will be im-
portant to consistently recognize and annotate NLSs and
NoLSs as distinct, which will undoubtedly lead to
improved predictions. A larger number of examples of
true NLS-only signals, NoLS-only signals and joint
NLS-NoLSs will help in better deﬁning these signals and
differentiating them. In addition to this, studies such as
this one should help in the construction of precisely
targeted fusion proteins, ensuring that proteins are not
highly enriched in the nucleolus when the aim is to
locate them in the nucleoplasm.
A small number of proteins have been proposed to act
as transporters to the nucleolus [e.g. B23/NPM1 which
shuttles between the cytoplasm and nucleolus and binds
several NoLS-containing proteins (28)]. Alternatively,
NoLSs might instead bind to nucleolar RNA thus
causing the targeting of the proteins that contain them
to the nucleolus. Further investigations will be required
to clarify whether protein transporters are widely used
for the nucleolar targeting of NoLS-containing proteins
or whether other mechanisms are predominantly
employed for this purpose. The NoLS predictions
should serve as a good starting point to experimentally
address these questions.
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